Evidence map›Paper›PMID 38111506›Full record

ArticleWorld journal of gastroenterology2023

Tenofovir amibufenamide

Wen-Ting Peng, Chuan Jiang, Fei-Lan Yang, Nian-Qi Zhou, Ke-Yu Chen, Jin-Qing Liu, Shi-Fang Peng, Lei Fu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. [Effect of switching from entecavir to tenofovir amibufenamide on HBsAg levels in patients with chronic hepatitis B: a 96-week real-world study].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  6. [APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Current status of drug therapy for chronic hepatitis B.World journal of gastroenterology · 2025
    Article
  17. Article
  18. [Comparison of the effects of tenofovir amibufenamide and tenofovir alafenamide on lipid metabolism in the body].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  19. [A case of successful treatment of acute exacerbation of chronic hepatitis B combined with abnormally elevated alpha-fetoprotein].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  20. [Let's start from practical for returning academics to the clinic].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wen-Ting PengDepartment of Infectious Diseases, Xiangya Hospital Central South University, Changsha 410008, Hunan Province, China.
Chuan JiangDepartment of Infectious Diseases, Xiangya Hospital Central South University, Changsha 410008, Hunan Province, China.
Fei-Lan YangDepartment of Infectious Diseases, Xiangya Hospital Central South University, Changsha 410008, Hunan Province, China.
Nian-Qi ZhouDepartment of Infectious Diseases, Xiangya Hospital Central South University, Changsha 410008, Hunan Province, China.
Ke-Yu ChenDepartment of Infectious Diseases, Xiangya Hospital Central South University, Changsha 410008, Hunan Province, China.
Jin-Qing LiuDepartment of Infectious Diseases, Xiangya Hospital Central South University, Changsha 410008, Hunan Province, China.
Shi-Fang PengDepartment of Infectious Diseases, Xiangya Hospital Central South University, Changsha 410008, Hunan Province, China.
Lei FuDepartment of Infectious Diseases, Xiangya Hospital Central South University, Changsha 410008, Hunan Province, China. fulei92@126.com.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy and safety profile of tenofovir amibufenamide (TMF) in chronic hepatitis B (CHB) patients is not well-established.

aimTo compare the efficacy and safety of TMF and tenofovir alafenamide (TAF) over a 48-wk period in patients with CHB.

methodsA total of 215 subjects meeting the inclusion criteria were enrolled and divided into two groups: TMF group (

resultsAt 24 and 48 wk, VR rates for the TMF group were 53.57% and 78.57%, respectively, compared with 48.31% and 78.65% for the TAF group (

conclusionOur study found TMF is as effective as TAF in treating CHB and has a comparable safety profile. However, TAF may be associated with worsening lipid profiles.

Indexed as

Antiviral AgentsHepatitis B, ChronicTenofovirAdenineAlanine TransaminaseHepatitis B e AntigensHumansLipidsLiver CirrhosisReverse Transcriptase InhibitorsAdenineAlanine TransaminaseAntiviral AgentsHepatitis B e AntigensLipidsReverse Transcriptase InhibitorsTenofovirAlanine transaminase normalizationBlood lipidChronic hepatitis BRenal safetyTenofovirVirological response

Identifiers

PMID38111506
PMCPMC10725562
OpenAlexW4389055042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.